Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Return on Capital Employed (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Return on Capital Employed for 10 consecutive years, with 4.27% as the latest value for Q1 2025.

  • On a quarterly basis, Return on Capital Employed fell 312.0% to 4.27% in Q1 2025 year-over-year; TTM through Mar 2025 was 4.27%, a 312.0% decrease, with the full-year FY2023 number at 0.94%, down 20.0% from a year prior.
  • Return on Capital Employed was 4.27% for Q1 2025 at Crescent Biopharma, down from 2.69% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.45% in Q1 2021 to a low of 4.27% in Q1 2025.
  • A 5-year average of 1.19% and a median of 0.89% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 31bps in 2023, then crashed -312bps in 2025.
  • Crescent Biopharma's Return on Capital Employed stood at 0.71% in 2021, then plummeted by -48bps to 1.05% in 2022, then increased by 12bps to 0.93% in 2023, then plummeted by -190bps to 2.69% in 2024, then plummeted by -59bps to 4.27% in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Return on Capital Employed are 4.27% (Q1 2025), 2.69% (Q3 2024), and 1.64% (Q2 2024).